Kangqiao Healthcare Industry Facility Platform: In-depth Empowerment through Subsidy Policies, Industrial Space, and Ecological Resources to Support High-quality Development of Medical Enterprises
Currently, the national centralized bulk procurement policy for medicines and medical consumables is deepening from "expansion" to "quality improvement" — the procurement categories have extended comprehensively from medicines to high-value medical consumables, general consumables, and other fields. The procurement rules continue to be optimized with industry development, not only driving medical product prices back to a reasonable range but also pushing companies to accelerate cost control, technological iteration, and product innovation through a "price and quality focus" approach. Many companies are facing the dual pressures of "cost reduction" and "innovation."
At the same time, the global medical industry landscape is entering a period of deep restructuring: some foreign pharmaceutical companies are accelerating the reorganization of their businesses in China due to strategic adjustments, either divesting mature pipelines or seeking localized supply chain cooperation; while domestic medical enterprises need to address core issues such as intensified market competition, balancing globalization and localization under the characteristics of high investment and long cycles in innovative R&D. "Breaking through capacity bottlenecks, exploring incremental markets, and linking industrial resources" have become common demands in the industry.
At this critical juncture of industrial transformation, how can medical companies survive, develop, and innovate amidst the changes? Recently, the "Kangqiao Innovation Empowerment" series – 2025 Kangqiao Qingpu Life Science Park Exchange Conference, hosted by Kangqiao Healthcare Industry Facility Platform and co-organized by Vbdata, successfully concluded. The event aimed to provide practical solutions for medical companies seeking breakthroughs, foster collaborative synergy within the life science industry, and inject new momentum into the high-quality development of the healthcare sector.
At the beginning of the event,Jiao Yang, Senior Investment Manager of Kangqiao Healthcare Industry Facility PlatformSystematically introducing the Kangqiao Healthcare Industry Facility Platform from the perspectives of policy support, capital background, business model, ecosystem resources, and supporting services.
Jiao Yang, Senior Investment Manager of Kangqiao Healthcare Industry Facility Platform
Kangqiao Qingpu Life Science Park, in cooperation with Qingpu Industrial Zone, provides quality policies for入驻 enterprises.
As a foreign-invested enterprise, CBC Group's businesses cover two major fields: equity investment and real estate investment. Its equity investment includes mergers and acquisitions as well as stable income strategies. In 2024, it acquired UCB’s neurology drug portfolio in Belgium. Additionally, the park can help入驻企业对接康桥生态圈资源、搭建合作桥梁.
The park has a total construction area of approximately 110,000 square meters, with hardware adapted to the entire life cycle of life science enterprises for R&D and production: equipped with photovoltaic systems, industrial steam, dual-circuit power supply (with reserved capacity for expansion), freight elevators with a load capacity of 2 tons and equipped with loading ports, and floor load-bearing meeting standards. Within one hour of transportation, it can reach the top life science industry clusters in the Yangtze River Delta region, and is only a 25-minute drive from Hongqiao Airport. Additionally, the park offers comprehensive supporting services and operational support, including government price-controlled apartments with rents lower than market intermediary prices; abundant nearby international school resources to meet employees' children’s educational needs. The park also features complete basic living facilities such as canteens and convenience stores, along with universal services like permit processing, environmental assessments, and recruitment support (under Qingpu District's Qingfeng Talent Policy).
Liu Menghan, Deputy Director of Business Development at Kangqiao Healthcare Industry Facility PlatformThe text systematically introduces the Kangqiao Healthcare Industry Facility Platform from the dimensions of core business strategy, industry empowerment capabilities, park planning and operation, ESG achievements, and cooperation adaptability.
Liu Menghan, Deputy Director of Business Development at Kangqiao Healthcare Industry Facility Platform
C-Bridge Capital was founded in 2014 and is headquartered in Singapore. Globally, C-Bridge Capital has established 12 offices, with over 10 billion US dollars under management, and in recent years has gradually expanded its RMB fund business.
At the business layout level, Kangqiao Capital has formed four core strategies: The first is the main fund, which focuses on a controlling-type approach. It has established multiple large health industry and M&A funds in partnership with Shunxi Capital, Beijing Yizhuang, and other partners to help park enterprises connect with invested enterprise resources and provide empowering support. The second is the real estate fund launched in 2021, which currently manages a scale of $875 million. It has implemented four industrial parks in Qingpu, Beijing, and Suzhou. Each park has different positioning — Daxing in Beijing, Qingpu, and Suzhou parks are more suitable for production needs, while Changping Park in Beijing focuses on biopharmaceutical R&D. The third is the bond/stable income fund, under which the US dollar fund has entered its second phase.
CBC Group Focuses on the Life Sciences and Healthcare Sector, Offering Enterprises Unique Services Such as Overseas Expansion Support and Sale-Leaseback Financing. Its Parks Are Designed and Developed by Professional Teams, Fully Compliant with GMP High Standards. The Life Science Industrial Park, LEED Gold-Certified at the Community Level, Ranked Third Globally in the 2023 GRESB Ratings. In the Future, CBC Group Plans to Explore Expansion into the Asia-Pacific Market, Providing Infrastructure Solutions to More Global Healthcare Companies.
During the interactive exchange session, numerous medical device and pharmaceutical industry chain-related enterprises present provided introductions on company positioning, product progress, technological advantages, financing status, commercialization, etc., and communicated their core demands with the Kangqiao Healthcare Industry Facility Platform respectively.
Kangqiao Healthcare Industry Platform can provide comprehensive and in-depth empowerment to medical enterprises from core dimensions such as policy funding, industrial space, ecological resources, operational support, and overseas expansion assistance. It offers targeted solutions such as "rent offset by renovation subsidies, compliant use of Class A warehouses, and ecological resource对接," promoting precise matching between enterprises and park resources.
Subsequently, the Kangqiao Healthcare Industry Platform will further advance the implementation of Qingpu Industrial Park policies, match enterprises' industrial space needs, and precisely connect ecosystem resources based on the cooperation intentions reached at this exchange meeting. It will continue to address practical issues for healthcare companies, such as cost reduction, innovation, and production capacity breakthroughs, while clearing development bottlenecks. By integrating resources and linking R&D, production, market, and other industry chain segments, it aims to drive the convergence of innovative forces in the life sciences field, providing strong support for building a more competitive healthcare industry ecosystem in China.